Alopecia is a medical term for hair loss, covering a wide range of conditions from gradual thinning to sudden, patchy baldness to permanent follicle destruction. Some forms are extremely common (pattern baldness affects the majority of men by age 50), while others are autoimmune conditions that can strike at any age. The type of alopecia determines whether hair can grow back and what treatments are available.
The Two Main Categories
All forms of alopecia fall into one of two groups: nonscarring and scarring. This distinction matters because it determines whether your hair loss is reversible.
In nonscarring alopecia, the hair follicles remain intact beneath the skin. The follicle may shrink, go dormant, or be attacked by the immune system, but it still exists. That means regrowth is possible, either on its own or with treatment. Nonscarring types are far more common.
In scarring (cicatricial) alopecia, the follicles are irreversibly destroyed and replaced by scar tissue. Once a follicle is gone, no treatment can bring it back. The goal with scarring alopecia is to stop the process before more follicles are lost. Scarring types are less common but more urgent to diagnose early.
Androgenetic Alopecia: Pattern Hair Loss
This is the most familiar type, often called male or female pattern baldness. It’s driven by a hormone called DHT, a potent form of testosterone. In people genetically prone to it, DHT binds to receptors on hair follicles and causes them to shrink a little more with each growth cycle. Over time, thick terminal hairs are replaced by fine, nearly invisible ones. The follicle isn’t dead, just miniaturized.
Men typically lose hair at the temples, the crown, and along the mid-forehead. Women tend to thin across the central scalp while keeping their front hairline mostly intact. The progression is gradual, often spanning years or decades.
Two treatments have strong evidence behind them. In a 12-month clinical trial comparing the two, oral finasteride (which blocks the conversion of testosterone to DHT) improved hair density in 80% of men, while topical minoxidil (which stimulates blood flow to follicles) improved it in 52%. Both are considered safe and effective, though finasteride is primarily used by men. Neither works overnight. Visible results typically take four to six months, and the benefit only lasts as long as you continue treatment.
Alopecia Areata: The Autoimmune Form
Alopecia areata is a condition where the immune system mistakenly attacks hair follicles. It typically appears as one or more smooth, round patches of bare skin on the scalp, though it can affect eyebrows, eyelashes, beards, and body hair. The skin in the bald patches looks normal, with no redness, flaking, or scarring. The lifetime risk of developing alopecia areata is about 2.1%, affecting roughly 2 out of every 1,000 people in the U.S. at any given time.
The underlying mechanism involves a breakdown in the immune “privilege” that normally protects hair follicles from immune surveillance. When that shield collapses, immune cells flood the follicle and release inflammatory signals that push hairs prematurely into their shedding phase. A feedback loop develops: certain immune cells release a key inflammatory protein, which causes skin cells to produce more signals that attract even more immune cells. This cycle keeps the follicle locked in a state of active inflammation, unable to grow new hair.
Alopecia areata can be unpredictable. Some people have a single episode with full regrowth. Others cycle through periods of loss and recovery. In more severe cases, it can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis).
Newer Treatments for Alopecia Areata
A class of medications called JAK inhibitors has changed the treatment landscape. These drugs interrupt the specific immune signaling pathways that drive the follicle attack. Three are now FDA-approved for alopecia areata, and their clinical trial results show meaningful regrowth for a significant number of patients.
Baricitinib helped 35 to 40% of patients achieve at least 80% scalp hair coverage by 36 weeks. Ritlecitinib showed similar promise, with 32% of patients reaching that threshold at 24 weeks, climbing to 61% after two years of continued treatment. Deuruxolitinib, the most recently approved, helped 41% of patients reach 80% or greater coverage by 24 weeks. These aren’t cures. They manage the immune response, and hair loss can return if you stop taking them.
Telogen Effluvium: Stress-Related Shedding
Telogen effluvium is a temporary, diffuse thinning that happens when a large number of hairs are pushed into their resting (shedding) phase at the same time. It typically shows up about three to four months after a triggering event: major surgery, high fever, severe emotional stress, crash dieting, childbirth, or stopping certain medications. You notice more hair in the drain or on your pillow, and the thinning is spread across the entire scalp rather than concentrated in patches.
The good news is that telogen effluvium is self-limiting. Shedding usually stops within three to six months once the trigger is removed. New hair begins growing in during that same window, but cosmetically noticeable recovery takes 12 to 18 months because hair only grows about half an inch per month.
Scarring Alopecias
Scarring alopecias are less common but more serious because they permanently destroy follicles. The damage happens when inflammation targets the upper portion of the follicle where stem cells reside. Once those stem cells are replaced by connective (scar) tissue, the follicle can never regenerate.
Frontal fibrosing alopecia causes a slowly progressing, symmetric recession of the hairline and primarily affects postmenopausal women. About 25% of patients notice itching or pain in the affected area, but many have no symptoms at all until they realize their hairline has moved back. Lichen planopilaris, another scarring type, tends to appear as irregular patches on the crown, often with redness, scaling around remaining hairs, and sensations of itching, burning, or tenderness.
Scarring alopecia can also result from external causes: radiation therapy, severe infections, chemical burns, or certain autoimmune skin diseases. A key visual difference from nonscarring types is the absence of visible follicle openings in the bald area. In nonscarring hair loss, you can still see tiny pores where follicles sit. In scarring alopecia, the skin looks smooth and featureless because the follicles have been replaced entirely.
How Alopecia Is Diagnosed
Diagnosis usually starts with a physical exam and a detailed history of when the hair loss began, how it’s progressed, and whether anything triggered it. A few specific tests help narrow things down.
The hair pull test is simple: a clinician grasps a small cluster of hairs and tugs gently. If more than a few come out easily, it suggests active shedding. The shape of the pulled hairs under magnification reveals a lot. Club-shaped, non-pigmented bulbs indicate telogen effluvium. Pencil-point tips and broken “exclamation mark” hairs are characteristic of alopecia areata. Hairs pulled with their roots still actively growing suggest a scarring process pulling follicles apart.
Trichoscopy, a magnified examination of the scalp surface, helps distinguish between types without a biopsy. In androgenetic alopecia, it reveals variation in hair thickness and an increased proportion of fine, short hairs. In scarring alopecia, it shows areas where follicle openings have disappeared entirely, sometimes with remaining hairs clumping together in tufts. A scalp biopsy is occasionally needed for scarring types to confirm the specific diagnosis and guide treatment.
The Psychological Weight of Hair Loss
Hair loss takes a larger emotional toll than many people expect. In a survey of 216 people with alopecia areata through the National Alopecia Areata Foundation, 85% said coping with the condition was a daily challenge, and 47% reported anxiety, depression, or both. On standardized mental health scales, over 60% of respondents scored in the borderline or abnormal range for anxiety.
One surprising finding: people with partial eyebrow loss reported greater anxiety and poorer quality of life than those who had lost their eyebrows completely. The in-between stage, where hair loss is visible but uneven, appears to create more distress than total loss, possibly because it’s harder to conceal or normalize. This psychological burden is a real and documented part of the disease, not a secondary concern.